Barclays analyst Carter Gould raised the firm’s price target on Merck to $130 from $128 and keeps an Overweight rating on the shares post the Q1 results. The analyst says Gardasil and Keytruda momentum provide near-term upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK: